CERS (CERS) Stock Price & Analysis
CERS (CERS) rose 0.78% to USD 2.59 as of September 8, 2026 at 09:33 UTC, according to Nexqual real-time market data.
CERS last closed at USD 2.59; the session ranged USD 2.54–2.6 on volume of 1,102,630 shares. Market capitalization is —, with a 52-week range of USD 1.17–3.47 (NGM). Source: Nexqual, September 8, 2026 at 09:33 UTC.
Key Statistics (as of September 8, 2026 at 09:33 UTC)
| Price | USD 2.59 |
|---|---|
| Change | ▲ 0.78% (up) |
| Previous Close | USD 2.59 |
| Open | USD 2.59 |
| Day Range | USD 2.54 – 2.6 |
| 52-Week Range | USD 1.17 – 3.47 |
| Volume | 1,102,630 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (CERS)
Nexqual's technical model rates CERS "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:33 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.97 (neutral) |
| vs SMA50 | Below (USD 2.82) |
| MACD | -0.04 (negative) |
From CERS's Latest SEC 10-K Filing (filed 2026-03-02)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGEN | Compugen Ltd. | USD 2.59 | ▼ 1.52% |
| VCYT | Veracyte, Inc. | USD 42.53 | ▼ 5.24% |
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 9.96 | ▼ 2.06% |
| MCRB | Seres Therapeutics, Inc. | USD 5.72 | ▲ 3.25% |
| CRIS | Curis, Inc. | USD 1.35 | ▼ 2.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:33 UTC. This page is informational and not investment advice.